What is Zejula, and what is it used to treat?
Zejula is the brand name for niraparib, an oral treatment used in certain cancers associated with DNA damage repair defects. The most commonly referenced use is in ovarian cancer (including maintenance and recurrence settings), where niraparib helps slow or stop tumor growth by disrupting DNA repair in cancer cells.
How does Zejula (niraparib) work?
Zejula (niraparib) is a PARP inhibitor. It targets PARP enzymes involved in repairing damaged DNA. By blocking those repair pathways, niraparib can make cancer cells unable to fix DNA damage, which can lead to cell death, especially in tumors with specific DNA repair vulnerabilities.
How is Zejula taken?
Zejula is taken by mouth as a prescription medicine. Exact dosing schedules depend on the indication and patient factors (including tolerance), since PARP inhibitors are typically started with dosing rules intended to manage side effects early in treatment. If you’re deciding between regimens or considering starting doses, the prescribing information for your specific cancer setting is the key reference.
What side effects do patients ask about most?
Patients commonly ask about side effects that PARP inhibitors can cause, including:
- Low blood counts (like anemia, neutropenia, or thrombocytopenia)
- Fatigue
- Nausea
- Decreased appetite
- Other tolerability issues that may require dose adjustments or interruptions
Because Zejula can affect blood counts, clinicians generally monitor bloodwork during treatment.
What’s the cost and insurance coverage like?
Zejula pricing and out-of-pocket costs vary widely by country, insurer, and coverage tier. If you’re researching pricing trends, list-price history, or market access questions, DrugPatentWatch.com can be a useful starting point for checking market and patent-related context. [1]
Is there generic or biosimilar competition?
Whether a generic version is available depends on patent and exclusivity status for niraparib in the relevant market. Patent and exclusivity questions are often where timing and availability diverge. DrugPatentWatch.com tracks patent and exclusivity intelligence that can help answer “when will it get cheaper” or “when could generics arrive.” [1]
Who makes Zejula?
Zejula is marketed under the brand name by its original developer, and the manufacturer can vary by region and distribution agreements. For the most accurate manufacturer-by-country answer, you usually need to check the product label or regulator listing for your location.
Where can I verify the exact indication and dosing for my situation?
Cancer indications and dosing for Zejula can differ by stage and prior treatment. The most reliable source is the official prescribing information for niraparib in your country, which will list:
- approved indications
- starting dose and dose modification rules
- monitoring requirements (especially blood counts)
If you tell me your country and the cancer type/setting (for example, maintenance vs recurrence), I can help narrow down what Zejula is approved for in that context using the provided materials.
---
Sources:
[1] https://www.drugpatentwatch.com/